Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation.

COVID-19 Convalescent plasma SARS-CoV-2 antibody escape evasion immune suppression mutation neutralising antibodies resistance

Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
29 Dec 2020
Historique:
pubmed: 6 1 2021
medline: 6 1 2021
entrez: 5 1 2021
Statut: epublish

Résumé

SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics are designed around Wuhan-1 Spike, this raises the theoretical possibility of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. Here we report chronic SARS-CoV-2 with reduced sensitivity to neutralising antibodies in an immune suppressed individual treated with convalescent plasma, generating whole genome ultradeep sequences by both short and long read technologies over 23 time points spanning 101 days. Although little change was observed in the overall viral population structure following two courses of remdesivir over the first 57 days, N501Y in Spike was transiently detected at day 55 and V157L in RdRp emerged. However, following convalescent plasma we observed large, dynamic virus population shifts, with the emergence of a dominant viral strain bearing D796H in S2 and

Identifiants

pubmed: 33398302
doi: 10.1101/2020.12.05.20241927
pmc: PMC7781345
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : Wellcome Trust
ID : 206618/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701652
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : R01 GM083127
Pays : United States

Commentaires et corrections

Type : UpdateIn

Auteurs

S A Kemp (SA)

Division of Infection and Immunity, University College London, London, UK.

D A Collier (DA)

Division of Infection and Immunity, University College London, London, UK.
Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

R Datir (R)

Division of Infection and Immunity, University College London, London, UK.
Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

Iatm Ferreira (I)

Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

S Gayed (S)

Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.

A Jahun (A)

Department of Pathology, University of Cambridge, Cambridge.

M Hosmillo (M)

Department of Pathology, University of Cambridge, Cambridge.

C Rees-Spear (C)

Division of Infection and Immunity, University College London, London, UK.

P Mlcochova (P)

Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

Ines Ushiro Lumb (IU)

NHS Blood and Transplant, Oxford and BRC Haematology Theme, University of Oxford, UK.

David J Roberts (DJ)

NHS Blood and Transplant, Oxford and BRC Haematology Theme, University of Oxford, UK.

Anita Chandra (A)

Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

N Temperton (N)

Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK.

K Sharrocks (K)

Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.

E Blane (E)

Department of Medicine, University of Cambridge, Cambridge, UK.

Jag Briggs (J)

Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.

Gils Mj van (GM)

Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.

Kgc Smith (K)

Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

J R Bradley (JR)

Department of Medicine, University of Cambridge, Cambridge, UK.
NIHR Cambridge Clinical Research Facility, Cambridge, UK.

C Smith (C)

Department of Virology, Cambridge University NHS Hospitals Foundation Trust.

R Doffinger (R)

Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital.

L Ceron-Gutierrez (L)

Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital.

G Barcenas-Morales (G)

Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital.

D D Pollock (DD)

Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, USA.

R A Goldstein (RA)

Division of Infection and Immunity, University College London, London, UK.

A Smielewska (A)

Department of Pathology, University of Cambridge, Cambridge.
Department of Virology, Cambridge University NHS Hospitals Foundation Trust.

J P Skittrall (JP)

Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
Department of Applied Mathematics and Theoretical Physics, University of Cambridge, UK.
Clinical Microbiology and Public Health Laboratory, Addenbrookes' Hospital, Cambridge, UK.

T Gouliouris (T)

Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.

I G Goodfellow (IG)

Department of Pathology, University of Cambridge, Cambridge.

E Gkrania-Klotsas (E)

Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.

Cjr Illingworth (C)

Department of Applied Mathematics and Theoretical Physics, University of Cambridge, UK.
MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

L E McCoy (LE)

Division of Infection and Immunity, University College London, London, UK.

R K Gupta (RK)

Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.
Africa Health Research Institute, Durban, South Africa.

Classifications MeSH